NTRK1 and colorectal carcinoma: CRC leads to a large number of cancer-related mortalities around the world, and KARAS mutations contribute to a poor prognosis and resistance to receptor tyrosine kinase (RTK) inhibitors and monoclonal antibodies against epidermal growth factor receptor (EGFR) (cetuximab and panitumumab), for example, in CRC patients (Karapetis et al., 2008).